MicroPort NeuroTech Limited (HK:2172)
:2172
Want to see HK:2172 full AI Analyst Report?
2172 Stock Chart & Stats
HK$11.30
HK$0.09(1.14%)
At close: 4:00 PM EST
HK$11.30
HK$0.09(1.14%)
Day’s Range― - ―
52-Week RangeHK$8.79 - HK$19.06
Previous CloseN/A
Volume491.15K
Average Volume (3M)2.57M
Market Cap
HK$5.28B
Enterprise ValueHK$3.88B
Total Cash (Recent Filing)HK$1.02B
Total Debt (Recent Filing)HK$15.95M
Price to Earnings (P/E)15.5
Beta0.91
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.5%
Share Statistics
EPS (TTM)0.32
Shares Outstanding585,034,800
10 Day Avg. Volume2,683,063
30 Day Avg. Volume2,571,422
Financial Highlights & Ratios
PEG Ratio-1.05
Price to Book (P/B)3.10
Price to Sales (P/S)7.24
P/FCF Ratio36.12
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$12.50Price Target Upside10.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.54
Revenue Forecast (FY)HK$873.93M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low debt and materially strengthened equity since 2021 give durable financial flexibility. This reduces refinancing and solvency risk, supports continued R&D and commercial investment, and preserves optionality for M&A or product rollouts during industry cycles.
High Gross MarginsA sustained gross margin profile near 72–78% indicates structural product-level pricing power and manufacturing leverage in neuromodulation. High margins underpin long-term operating profitability and capacity to fund R&D, clinical studies, and commercialization without immediate capital strain.
Improving Free Cash FlowRecovery from a 2023 cash deficit to positive FCF in 2024–25 shows improving cash generation capacity. Sustained FCF supports reinvestment in product development and after-sales support and lowers reliance on external funding for strategic initiatives over the medium term.
Bears Say
Earnings VolatilityMaterial swings in profitability—loss in 2022, rebound, then decline in 2025—create uncertainty in sustainable earnings power. For a med-tech company, this complicates long-term planning for clinical investment, capacity expansion, and consistent stakeholder returns.
Inconsistent Cash ConversionRepeated instances where operating cash falls short of net income indicate weaker earnings quality and working-capital swings. Persisting conversion gaps raise risk that earnings cannot reliably fund growth or buffer reimbursement and pricing pressures over the medium term.
Modest Revenue & EPS GrowthLow single-digit revenue growth and a large negative EPS change signal constrained top-line momentum and near-term margin pressure. Slower growth undermines scaling benefits in R&D amortization and commercial leverage, making competitive positioning harder in a capital-intensive med-tech sector.
MicroPort NeuroTech Limited News
2172 FAQ
What was MicroPort NeuroTech Limited’s price range in the past 12 months?
MicroPort NeuroTech Limited lowest stock price was HK$8.79 and its highest was HK$19.06 in the past 12 months.
What is MicroPort NeuroTech Limited’s market cap?
MicroPort NeuroTech Limited’s market cap is HK$5.28B.
When is MicroPort NeuroTech Limited’s upcoming earnings report date?
MicroPort NeuroTech Limited’s upcoming earnings report date is Sep 02, 2026 which is in 103 days.
How were MicroPort NeuroTech Limited’s earnings last quarter?
MicroPort NeuroTech Limited released its earnings results on Mar 25, 2026. The company reported HK$0.172 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.172.
Is MicroPort NeuroTech Limited overvalued?
According to Wall Street analysts MicroPort NeuroTech Limited’s price is currently Undervalued.
Does MicroPort NeuroTech Limited pay dividends?
MicroPort NeuroTech Limited pays a Quarterly dividend of HK$0.05 which represents an annual dividend yield of 1.5%. See more information on MicroPort NeuroTech Limited dividends here
What is MicroPort NeuroTech Limited’s EPS estimate?
MicroPort NeuroTech Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MicroPort NeuroTech Limited have?
MicroPort NeuroTech Limited has 585,034,800 shares outstanding.
What happened to MicroPort NeuroTech Limited’s price movement after its last earnings report?
MicroPort NeuroTech Limited reported an EPS of HK$0.172 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.698%.
Which hedge fund is a major shareholder of MicroPort NeuroTech Limited?
Currently, no hedge funds are holding shares in HK:2172
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MicroPort NeuroTech Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
18.98%
12-Months-Change
Fundamentals
Return on Equity
10.38%
Trailing 12-Months
Asset Growth
8.01%
Trailing 12-Months
Company Description
MicroPort NeuroTech Limited
MicroPort NeuroTech Limited engages in the research and development, production, and sale of neuro-interventional medical devices in the People's Republic of China and internationally. It offers NUMEN, a coil embolization system; NUMEN FR, a coil detachment system; Tubridge, a flow-diverting stent; Willis, an intracranial stent graft system; and Rebridge, an intracranial visualized stent for use in the treatment of hemorrhagic stroke. The company also provides APOLLO, an intracranial arterial stent system to treat intracranial atherosclerotic disease; and Bridge, a rapamycin target eluting vertebral artery stent system to treat cerebral atherosclerotic stenosis. In addition, it offers Neurohawk, a stent thrombectomy device; Tigertriever, an adjustable stent retriever for use in the treatment of acute ischemic stroke. The company was founded in 2004 and is headquartered in Shanghai, the People's Republic of China.
2172 Stock 12 Month Forecast
Average Price Target
HK$12.50
▲(10.62% Upside)
Technical Analysis
Peijia Medical Ltd.
―
Zylox-Tonbridge Medical Technology Co., Ltd. Class H
―
LifeTech Scientific Corporation
―
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H
―
MicroPort CardioFlow Medtech Corp.
―
Options Prices
Currently, No data available
---